alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 522.1664 Oxytetracycline and flunixin. ( a ) *Specifications.* Each milliliter (mL) of solution contains 300 milligrams (mg) oxytetracycline base as amphoteric oxytetracycline and 20 mg flunixin base as flunixin meglumine.
( b ) *Sponsor.* See No. 055529 in § 510.600(c) of this chapter.
( c ) *Related tolerances.* See §§ 556.286 and 556.500 of this chapter.
( d ) *Conditions of use cattle* — ( 1 ) *Amount.* Administer once as an intramuscular or subcutaneous injection of 1 mL per 22 pounds (lb) body weight (BW) (13.6 mg oxytetracycline and 0.9 mg flunixin per lb BW) where retreatment of calves and yearlings for bacterial pneumonia is impractical due to husbandry conditions, such as cattle on range, or where their repeated restraint is inadvisable.
( 2 ) *Indications for use.* For the treatment of bacterial pneumonia associated with *Pasteurella* spp. and for the control of associated pyrexia in beef and nonlactating dairy cattle.
( 3 ) *Limitations.* Discontinue treatment at least 21 days prior to slaughter of cattle. This drug product is not approved for use in female dairy cattle 20 months of age or older, including dry dairy cows. Use in these cattle may cause drug residues in milk and/or in calves born to these cows. A withdrawal period has not been established in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[76 FR 3489, Jan. 20, 2011, as amended at 79 FR 16192, Mar. 25, 2014]
§ 522.728 Dipyrone. ( a ) *Specifications.* Each milliliter of solution contains 500 milligrams (mg) dipyrone.
( b ) *Sponsor.* See No. 043264 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* Administer 30 mg per kilogram of body weight (13.6 mg per pound) by intravenous injection, once or twice daily at a 12-hour interval for up to 3 days.
( 2 ) *Indications for use.* For control of pyrexia in horses.
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Do not use in any food-producing animals, including lactating dairy animals. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[85 FR 18119, Apr. 1, 2020, as amended at 88 FR 14898, Mar. 10, 2023]
EXHIBIT 21

                        RICHTON INTERNATIONAL CORPORATION
                        ---------------------------------

                          SUBSIDIARIES OF REGISTRANTS:
                          ----------------------------

                        1. Richton Holding Company

                        2. Century Supply Corp.

                        3. Century Supply Corp of Canada Ltd.

                        4. CBE Technologies, Inc.

                        5. Creative Business Concepts, Inc.
<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
     THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
     QUARTERLY REPORT 10-Q AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
     FINANCIAL STATEMENTS. 
</LEGEND>
<CIK>                         0000813807
<NAME>                        COURTYARD BY MARRIOTT LIMITED PARTNERSHIP
<MULTIPLIER>                                   1,000
<CURRENCY>                                     U.S. DOLLAR
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              DEC-31-1998
<PERIOD-START>                                 JAN-01-1998
<PERIOD-END>                                   MAR-27-1998
<EXCHANGE-RATE>                                1.00
<CASH>                                         9,677
<SECURITIES>                                   0
<RECEIVABLES>                                  5,927
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                               14,167
<PP&E>                                         535,336
<DEPRECIATION>                                 (231,405)
<TOTAL-ASSETS>                                 333,702
<CURRENT-LIABILITIES>                          41,860
<BONDS>                                        318,622
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       0
<OTHER-SE>                                     (26,780)
<TOTAL-LIABILITY-AND-EQUITY>                   333,702
<SALES>                                        0
<TOTAL-REVENUES>                               23,777
<CGS>                                          0
<TOTAL-COSTS>                                  0
<OTHER-EXPENSES>                               12,719
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             6,253
<INCOME-PRETAX>                                4,805
<INCOME-TAX>                                   0
<INCOME-CONTINUING>                            0
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   4,805
<EPS-PRIMARY>                                  0
<EPS-DILUTED>                                  0
        


</TABLE>
<PAGE>   1
                                                                    EXHIBIT 23.1



                         Consent of Independent Auditors


We consent to the incorporation by reference in the Registration Statement (Form
S-8) pertaining to the Wall Data Incorporated 1994 Restated Nonofficer Stock
Option Plan as Amended and Restated on October 15, 1996, of our reports dated 
May 18, 1998 and January 19,1998, except Note 14 as to which the date is March 
12, 1998, with respect to the consolidated financial statements and schedule of
Wall Data Incorporated included in the Transition Report on Form 10-K for the 
four months ended April 30, 1998, and the Annual Report on Form 10-K for the 
year ended December 31,1997, respectively, filed with the Securities and 
Exchange Commission.

                                                     /s/ ERNST & YOUNG LLP

Seattle, Washington
December 17, 1998
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                       1,238,581
<SECURITIES>                                         0
<RECEIVABLES>                                1,355,005
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                             2,905,697
<PP&E>                                      68,269,709
<DEPRECIATION>                              28,887,486
<TOTAL-ASSETS>                              92,421,978
<CURRENT-LIABILITIES>                        7,821,189
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             0
<OTHER-SE>                                  22,221,432
<TOTAL-LIABILITY-AND-EQUITY>                92,421,978
<SALES>                                              0
<TOTAL-REVENUES>                            39,517,808
<CGS>                                                0
<TOTAL-COSTS>                               34,929,245
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                          10,240,023
<INCOME-PRETAX>                            (5,550,635)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (5,550,635)
<EPS-PRIMARY>                                        0
<EPS-DILUTED>                                        0


</TABLE>
EXHIBIT 32.1
                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                    AS ADOPTED PURSUANT TO SECTION 906 OF THE
                           SARBANES-OXLEY ACT OF 2002

In connection  with the  quarterly  report of Avitar,  Inc.  (the  "Company") on
Form10-QSB  for the period ending June 30, 2004 as filed with the Securities and
Exchange  Commission on the date hereof (the  "Report"),  I, Peter P.  Phildius,
Chief Executive  Officer of the Company certify,  pursuant to 18 U.S.C.  Section
1350, as adopted pursuant to Section 906 of the  Sarbanes-Oxley  Act of 2002, to
my knowledge, that:

     (1) The Report  fully  complies  with the  requirements  of  Section  13(a)
or15(d) of the Securities Exchange Act of 1934; and

     (2)  The  information  contained  in the  Report  fairly  presents,  in all
material  respects,  the  financial  condition  and results of operations of the
Company.

Date: August 18, 2004

                                          /s/ Peter P. Phildius
                                          ---------------------
                                          Peter P. Phildius
                                          Chief Executive Officer
I 

118TH CONGRESS 

2D SESSION H. R. 7346 

To amend the Public Health Service Act to provide for the continued implementation of the Climate and Health program by the Centers for Disease 

Control and Prevention. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 14, 2024 

Ms. UNDERWOOD (for herself, Mr. PAYNE, Ms. BROWN, Mr. GARCI ́A of Illinois, Ms. SEWELL, Ms. PLASKETT, Mrs. WATSON COLEMAN, Ms. SCHAKOWSKY, Ms. ADAMS, Ms. NORTON, Ms. LEE of Pennsylvania, and Ms. 

JACOBS) introduced the following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To amend the Public Health Service Act to provide for 

the continued implementation of the Climate and Health 

program by the Centers for Disease Control and Prevention. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Climate and Health 

5 Protection Act’’. 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7346 IH

1 SEC. 2. CONTINUED IMPLEMENTATION OF THE CLIMATE 

2 AND HEALTH PROGRAM. 

3 Part B of title III of the Public Health Service Act 

4 is amended by inserting after section 317U (42 U.S.C. 

5 247b–23) the following new section: 

6 ‘‘SEC. 317V. CLIMATE AND HEALTH PROGRAM. 

7 ‘‘(a) IN GENERAL.—The Secretary, acting through 

8 the Director of the Centers for Disease Control and Pre9 vention, shall continue to implement the Climate and 

10 Health program carried out by the National Center for 

11 Environmental Health (or successor program) for the fol12 lowing purposes: 

13 ‘‘(1) To translate climate change science to in14 form State, local, and Tribal governments, including 

15 health departments, as well as communities. 

16 ‘‘(2) To create decision support tools to build 

17 capacity to prepare for climate change. 

18 ‘‘(3) To serve as a credible leader in planning 

19 for the public health impacts of climate change. 

20 ‘‘(b) WRITTEN NOTIFICATION TO CONGRESS.—In 

21 the case of the establishment of any successor program 

22 to the Climate and Health program referred to in sub23 section (a), the Secretary, acting through the Director of 

24 the Centers for Disease Control and Prevention, shall sub25 mit to Congress a written notification of any transfer or 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•HR 7346 IH

1 reprogramming of funds to establish such a successor pro2 gram. 

3 ‘‘(c) AUTHORIZATION OF APPROPRIATIONS.— 

4 ‘‘(1) IN GENERAL.—There are authorized to be 

5 appropriated to carry out the program referred to in 

6 subsection (a) $110,000,000 for fiscal year 2024 

7 and each fiscal year thereafter. 

8 ‘‘(2) LIMITATION.—None of the funds made 

9 available under paragraph (1) may be transferred or 

10 reprogrammed by the Secretary to carry out another 

11 program administered by the Secretary.’’. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
DISTRICT COURT OF APPEAL OF FLORIDA

SECOND DISTRICT

MICHAEL JOSEPH NACHREINER,

Appellant,

v.

STATE OF FLORIDA,

Appellee.

No. 2D22-2195

November 15, 2023

Appeal from the Circuit Court for Pasco County; Mary M. Handsel, 

Judge.

Howard L. Dimmig, II, Public Defender, and Clark E. Green, Assistant 

Public Defender, Bartow, for Appellant.

Ashley Moody, Attorney General, Tallahassee, and Natalia ReynaPimiento, Assistant Attorney General, Tampa, for Appellee.

PER CURIAM.

Affirmed.

SILBERMAN, LaROSE, and ATKINSON, JJ., Concur.

Opinion subject to revision prior to official publication.
kop-ex10111_428.htm



 

Exhibit 10.111

AMENDMENT NO. 1

TO

KEY EMPLOYEE

NON-COMPETITION AGREEMENT

AMENDMENT NO. 1, made and entered into this 2nd day of April, 2012 between Osmose Holdings, Inc., a Delaware corporation duly organized and validly existing under the laws of the State of Delaware, having a place of business at 980 Ellicott Street, Buffalo., New York 14209, and Stephen C. Reeder, residing at 2870 Clegg Farm Road, Social Circle, Georgia 30025, hereinafter referred to as the “Employee” Unless otherwise specified, the term “Corporation” as used in this Amendment No. 1 shall mean collectively Osmose Holdings, Inc. and all of its subsidiaries and affiliates (“Osmose Affiliates”), and any reference to. Employee’s employment with the Corporation shall be deemed to refer to Employee's employment with the specific Osmose Affiliate for which he/she is employed.

WHEREAS, the Employee is employed by the Corporation; and

WHEREAS, the Corporation and the Employee are parties to a Key Employee Non­ Competition Agreement dated November 8, 2006 (the “Agreement”) pursuant to which, among other things, the Employee may become eligible to receive a Retirement Benefit pursuant to Section 4 of, and otherwise subject to all other terms and conditions of, the Agreement; and

WHEREAS, in recognition of the continued valuable service of the Employee with and for the Corporation the Corporation has agreed to adjust the amount of the Retirement Benefit to which the Employee may become eligible, as set forth in this Amendment No. 1.

NOW, THEREFORE, in consideration of the foregoing and of the mutual promises contained in this Amendment No. 1, the Corporation and the Employee consent, covenant and agree as follows:


	
 
	
1.
	
Defined Terms. Defined terms used in this Amendment No, 1 but not defined in this Amendment No. 1 shall have the meaning set forth in the Agreement.





	
 
	
2.
	
Current Title. The Employee's current position is as follows: Sr. Vice President of U.S. Wood Preserving of Osmose, Inc.





	
 
	
3.
	
Adjustment of Retirement Benefit. Effective as of the date of this Amendment No. 1, the amount of the Retirement Benefit set forth in Section 4.a. of the Agreement is hereby amended to be $300,000.





	
 
	
4.
	
All Other Terms Remain in Effect. Except as specifically set forth in this Amendment No. 1, all other provisions, terms and conditions of the Agreement are unchanged and remain in full force and effect.




 



 

IN WITNESS WHEREOF, the Employee and the Corporation have executed this Amendment No. 1 as of the date set forth at the beginning of this Agreement.

 


		
	
EMPLOYEE

	
 

	
Stephen C. Reeder

	
 

	
(Typed Name)

	
 

	
/s/ Stephen C. Reeder L.S.

	
 

	
(Signature)

	
 

	
 

	
OSMOSE HOLDINGS, INC.

	
 

	
By 
	
/s/ James R. Spengler, Jr.

	
 
	
James R. Spengler, Jr.

	
 
	
President & CEO




 

2
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7436 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7436

  To direct the Comptroller General of the United States to prepare a 
     report on Federal efforts to address antimicrobial resistance.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                           February 23, 2024

 Mr. Griffith introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL

 
  To direct the Comptroller General of the United States to prepare a 
     report on Federal efforts to address antimicrobial resistance.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Antimicrobial Resistance Research 
Assessment Act of 2024''.

SEC. 2. REPORT ON FEDERAL EFFORTS TO ADDRESS ANTIMICROBIAL RESISTANCE.

    (a) In General.--The Comptroller General of the United States 
shall--
            (1) prepare a report on efforts of the Federal Government 
        to address antimicrobial resistance; and
            (2) not later than 1 year after the date of enactment of 
        this Act--
                    (A) finalize such report; and
                    (B) submit such report to the Congress.
    (b) Contents.--The report required by subsection (a) shall--
            (1) address all efforts of the Federal Government regarding 
        antimicrobial resistance, including any such efforts 
        involving--
                    (A) establishing, maintaining, or operating a task 
                force, committee, or interagency program; or
                    (B) developing a plan or report;
            (2) specify the role of each Federal program and resource 
        in such efforts;
            (3) identify any such efforts that are duplicative;
            (4) recommend ways to improve the coordination of such 
        efforts across the Federal Government;
            (5) identify the results achieved thus far through such 
        efforts;
            (6) describe any such efforts related to phage therapy; and
            (7) with respect to research being federally conducted or 
        supported with respect to antimicrobial resistance--
                    (A) quantify of the costs of such research;
                    (B) if any such research is identified as 
                duplicative pursuant to paragraph (3), recommend 
                approaches for coordinating or consolidating such 
                research to avoid duplication; and
                    (C) recommend whether there should be a central 
                Federal agency to oversee such research.
                                 <all>
```
Order entered March 19, 2013

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-13-00192-CV

IN RE JOHN CLOUD, Relator

On Appeal from the 195th Judicial District Court

Dallas County, Texas

Trial Court Cause No. F93-61603

ORDER

Based on the Court’s opinion of this date, we DENY relator’s petition for writ of 

mandamus. We ORDER that relator bear the costs of this original proceeding.

.

/Jim Moseley/

____________________________

JIM MOSELEY 

JUSTICE
§ 524.1580c Nitrofurazone and butacaine ointment. ( a ) *Specifications.* The drug contains 0.2 percent nitrofurazone and 0.5 percent butacaine sulfate in a water-soluble base.
( b ) *Sponsor.* See No. 054925 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Indications for use.* For prevention or treatment of surface bacterial infections of ears, wounds, burns, and cutaneous ulcers of dogs, cats, and horses.
( 2 ) *Limitations.* Apply directly on the lesion with a spatula or first place on a piece of gauze. Use of a bandage is optional. The preparation should remain on the lesion for at least 24 hours. The dressing may be changed several times daily or left on the lesion for a longer period. For use only on dogs, cats, and horses (not for food use). In case of deep or puncture wounds or serious burns, use only as recommended by a veterinarian. If redness, irritation, or swelling persists or increases, discontinue use; consult veterinarian.
[49 FR 9417, Mar. 13, 1984, as amended at 71 FR 13542, Mar. 16, 2006. Redesignated at 79 FR 10971, Feb. 27, 2014; 79 FR 10971, Feb. 27, 2014]
IIB 

118TH CONGRESS 

1ST SESSION H. R. 753 

IN THE SENATE OF THE UNITED STATES 

MARCH 9, 2023 

Received; read twice and referred to the Committee on Veterans’ Affairs 

AN ACT 

To direct the Secretary of Veterans Affairs to use on-site 

regulated medical waste treatment systems at certain 

Department of Veterans Affairs facilities, and for other 

purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


pbinns on DSKJLVW7X2PROD with $$_JOB
2 

HR 753 RFS

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Department of Vet3 erans Affairs Creation of On-Site Treatment Systems Af4 fording Veterans Improvements and Numerous General 

5 Safety Enhancements Act’’ or the ‘‘VA COST SAVINGS 

6 Enhancements Act’’. 

7 SEC. 2. USE OF ON-SITE REGULATED MEDICAL WASTE 

8 TREATMENT SYSTEMS AT DEPARTMENT OF 

9 VETERANS AFFAIRS FACILITIES. 

10 (a) IDENTIFICATION OF FACILITIES.—The Secretary 

11 of Veterans Affairs shall identify Department of Veterans 

12 Affairs facilities that would benefit from cost savings asso13 ciated with the use of an on-site regulated medical waste 

14 treatment system over a five-year period. 

15 (b) REGULATED MEDICAL WASTE COST ANALYSIS

16 MODEL.—For purposes of carrying out subsection (a), the 

17 Secretary shall develop a uniform regulated medical waste 

18 cost analysis model to be used to determine the cost sav19 ings associated with the use of an on-site regulated med20 ical waste treatment system at Department facilities. Such 

21 model shall be designed to calculate savings based on— 

22 (1) the cost of treating regulated medical waste 

23 at an off-site location under a contract with a non24 Department entity; compared to 

25 (2) the cost of treating regulated medical waste 

26 on-site, based on the equipment specification of 


pbinns on DSKJLVW7X2PROD with $$_JOB
3 

HR 753 RFS

1 treatment system manufacturers, with capital costs 

2 amortized over a ten-year period. 

3 (c) INSTALLATION.—At each Department facility 

4 identified under subsection (a), the Secretary shall secure, 

5 install, and operate an on-site regulated medical waste 

6 treatment system. 

7 (d) REGULATED MEDICAL WASTE DEFINED.—In 

8 this section, the term ‘‘regulated medical waste’’ has the 

9 meaning given such term under section 173.134(a)(5) of 

10 title 49, Code of Federal Regulations, concerning regu11 lated medical waste and infectious substances, or any suc12 cessor regulation, except that, in the case of an applicable 

13 State law that is more expansive, the definition in the 

14 State law shall apply. 

15 SEC. 3. NO ADDITIONAL FUNDS AUTHORIZED. 

16 No additional funds are authorized to be appro17 priated to carry out the requirements of this Act. 

Passed the House of Representatives March 8, 

2023. 

Attest: CHERYL L. JOHNSON, 

Clerk. 


pbinns on DSKJLVW7X2PROD with $$_JOB
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA

F OURTH D ISTRICT

JOHN GOICOECHEA
, Appellant,

v.

STATE OF FLORIDA
, Appellee

.

No. 4D 21

- 312

[ September 30, 2021 ]

Appeal from the County Court for the Seventeenth J udicial Circuit, Broward County ; Mindy F. Solomon , Judge; L.T. Case No s

. 17

- 002720

- MM10A and 18

- 000042AC10A

.

Howard Finkelstein, Public Defender, and Sarah W. Sandler, Assistant Public Defender, Fort Lauderdale, for appellant

.

Ashley B. Moody, Attorney General, Tallahassee, and Alexandr a A. Folley, Assistant Attorney General, West Palm Beach, for appellee.

P ER C URIAM

.

Affirmed.

G ROSS
, M AY and D A MOORGIAN
, JJ., concur

.

* * *

Not final until disposition of timely filed motion for rehearing.